Standout Papers

Cancer immunotherapy using checkpoint blockad... 2009 2026 2014 2020 4.4k
  1. Cancer immunotherapy using checkpoint blockade (2018)
    Antoni Ribas, Jedd D. Wolchok Science
  2. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria (2009)
    Jedd D. Wolchok, Axel Hoos et al. Clinical Cancer Research
  3. Immune Checkpoint Blockade in Cancer Therapy (2015)
    Michael A. Postow, Margaret K. Callahan et al. Journal of Clinical Oncology
  4. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations (2016)
    Weiping Zou, Jedd D. Wolchok et al. Science Translational Medicine
  5. Antibody therapy of cancer (2012)
    Andrew M. Scott, Jedd D. Wolchok et al. Nature reviews. Cancer
  6. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma (2015)
    Dirk Schadendorf, F. Stephen Hodi et al. Journal of Clinical Oncology
  7. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics (2017)
    Lesley Seymour, Jan Bogaerts et al. The Lancet Oncology
  8. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies (2015)
    Jarushka Naidoo, David B. Page et al. Annals of Oncology
  9. RECIST 1.1—Update and clarification: From the RECIST committee (2016)
    Lawrence H. Schwartz, Saskia Litière et al. European Journal of Cancer
  10. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma (2013)
    Tyler R. Simpson, Fubin Li et al. The Journal of Experimental Medicine
  11. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial (2018)
    F. Stephen Hodi, Vanna Chiarion‐Sileni et al. The Lancet Oncology
  12. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study (2009)
    Jedd D. Wolchok, Bart Neyns et al. The Lancet Oncology
  13. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy (2016)
    Danny N. Khalil, Eric L. Smith et al. Nature Reviews Clinical Oncology
  14. Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma (2017)
    Jeffrey S. Weber, F. Stephen Hodi et al. Journal of Clinical Oncology
  15. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial (2012)
    Kim Margolin, Marc S. Ernstoff et al. The Lancet Oncology
  16. Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center (2015)
    Troy Z. Horvat, Nelly G. Adel et al. Journal of Clinical Oncology
  17. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis (2016)
    Krista Dubin, Margaret K. Callahan et al. Nature Communications
  18. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001 (2019)
    Omid Hamid, Caroline Robert et al. Annals of Oncology
  19. Chromatin states define tumour-specific T cell dysfunction and reprogramming (2017)
    Mary Philip, Lauren Fairchild et al. Nature
  20. Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy (2014)
    Dmitriy Zamarin, Rikke Holmgaard et al. Science Translational Medicine
  21. Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody (2014)
    Shintaro Iwama, Alessandra De Remigis et al. Science Translational Medicine
  22. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways (2021)
    Lukas Kraehenbuehl, Chien‐Huan Weng et al. Nature Reviews Clinical Oncology
  23. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4 (2013)
    Rikke Holmgaard, Dmitriy Zamarin et al. The Journal of Experimental Medicine
  24. The future of cancer immunotherapy: microenvironment-targeting combinations (2020)
    Yonina R. Murciano‐Goroff, Allison Betof Warner et al. Cell Research
  25. Cancer immunotherapy — immune checkpoint blockade and associated endocrinopathies (2017)
    David J. Byun, Jedd D. Wolchok et al. Nature Reviews Endocrinology
  26. Clinical implications of T cell exhaustion for cancer immunotherapy (2022)
    Andrew Chow, Karlo Perica et al. Nature Reviews Clinical Oncology
  27. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps (2011)
    Padmanee Sharma, Klaus W. Wagner et al. Nature reviews. Cancer
  28. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer (2016)
    Juan C. Osorio, Ai Ni et al. Annals of Oncology
  29. CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors (2020)
    Haiping Wang, Fabien Franco et al. Nature Immunology
  30. A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy (2017)
    Marta Łuksza, Nadeem Riaz et al. Nature
  31. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors (2016)
    Frank B. Cortazar, Kristen A. Marrone et al. Kidney International
  32. Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas (2012)
    Piro Lito, Christine A. Pratilas et al. Cancer Cell
  33. Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies (2018)
    Roberta Zappasodi, Taha Merghoub et al. Cancer Cell
  34. MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma (2018)
    Scott J. Rodig, Daniel Gusenleitner et al. Science Translational Medicine
  35. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido (2011)
    Vinod P. Balachandran, Michael J. Cavnar et al. Nature Medicine
  36. Immune Modulation in Cancer with Antibodies (2013)
    David B. Page, Michael A. Postow et al. Annual Review of Medicine
  37. Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab (2019)
    Suzanne L. Topalian, F. Stephen Hodi et al. JAMA Oncology
  38. The hallmarks of successful anticancer immunotherapy (2018)
    Lorenzo Galluzzi, Timothy A. Chan et al. Science Translational Medicine
  39. Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers (2018)
    Min Yuen Teo, Kenneth Seier et al. Journal of Clinical Oncology
  40. Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner (2015)
    Rikke Holmgaard, Dmitriy Zamarin et al. Cell Reports
  41. Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial (2010)
    Bradley Curtis Carthon, Jedd D. Wolchok et al. Clinical Cancer Research
  42. Single‐institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting (2010)
    Geoffrey Y. Ku, Jianda Yuan et al. Cancer
  43. Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine (2020)
    Luís Felipe Campesato, Sadna Budhu et al. Nature Communications
  44. Monoclonal Antibodies for Cancer Therapy (2012)
    Andrew M. Scott, James P. Allison et al. SpringerReference
  45. Integrated NY-ESO-1 antibody and CD8+T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab (2011)
    Jianda Yuan, Matthew Adamow et al. Proceedings of the National Academy of Sciences
  46. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma (2013)
    Jedd D. Wolchok, F. Stephen Hodi et al. Annals of the New York Academy of Sciences

Immediate Impact

64 by Nobel laureates 78 from Science/Nature 299 standout
Sub-graph 1 of 17

Citing Papers

Neuronal substance P drives metastasis through an extracellular RNA–TLR7 axis
2024 StandoutNature
Targeting PD-L2–RGMb overcomes microbiome-related immunotherapy resistance
2023 StandoutNature
6 intermediate papers

Works of Jedd D. Wolchok being referenced

Cancer immunotherapy using checkpoint blockade
2018 StandoutScience
Targeting T Cell Co-receptors for Cancer Therapy
2016
and 8 more

Author Peers

Author Last Decade Papers Cites
Jedd D. Wolchok 44357 29224 15851 558 63.2k
James P. Allison 38454 49382 12845 480 70.9k
Drew M. Pardoll 44257 46168 23146 398 81.6k
Antoni Ribas 38917 22192 26896 548 59.5k
Gordon J. Freeman 37868 53470 14403 418 81.0k
Mark J. Smyth 36937 52200 19880 592 80.1k
Wolf H. Fridman 27029 30637 16241 524 56.0k
Lieping Chen 33760 35531 9061 366 54.6k
Suzanne L. Topalian 32079 26635 12249 211 48.3k
F. Stephen Hodi 33441 16392 10242 509 42.8k
Seth M. Steinberg 28549 12611 15293 861 57.6k

All Works

Loading papers...

Rankless by CCL
2026